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Intracellular citrate is a central component of the tricarbox-
ylic acid cycle; its excretion in the urine was utilized by Krebs
and coworkers to demonstrate this biochemical pathway in
whole animals. Subsequently, urinary citrate has been viewed
as a "window" on renal metabolism [I]. Additionally, renal
physiologists and biochemists have been intrigued for decades
by the dramatic changes in urinary citrate which occur with
changes in acid-base homeostasis. In recent years, renal han-
dling of citrate and citrate excretion in the urine have attracted
renewed interest because of several considerations. First, mod-
ern techniques in renal physiology (such as, transport studies in
brush border membrane vesicles and perfused proximal tu-
bules) have provided insights into the cellular and molecular
mechanisms of citrate transport [2]. Also, excretion of urinary
citrate (and other organic anions) has been recognized to
influence systemic acid-base status, at least in certain species
[3]. And perhaps most importantly, urinary citrate has been
increasingly recognized as an important endogenous inhibitor of
calcium nephrolithiasis [4]. This review will focus on the renal
handling of citrate, particularly the mechanisms of citrate
transport in the proximal tubule, and briefly discuss other
aspects of citrate metabolism.
Citrate is a tricarboxylic acid with pKa's of 2.9, 4.3, and 5.6.
Citric Acid — citrate1 —* citrate2 —* citrate3
Since the highest pKa of citrate is significantly below physio-
logic pH, citrate is predominantly trivalent (citrate3) in plasma
(Fig. 1). Plasma levels of total citrate are low, averaging 0.1 mM
in normal subjects in a recent study [5]. Also, much of plasma
(and urine) citrate is complexed to calcium, magnesium and
sodium [6, 71. The significance of this complexation for citrate
transport has not been addressed. Plasma citrate appears to be
relatively independent of normal dietary intake of citrate,
probably because of rapid metabolism after gut absorption.
However, plasma citrate does increase after oral citrate loads
[8, 9]. Besides intestinal reabsorption of citrate, bone is the
other major source (or reservoir) of plasma citrate. Utilization
of citrate occurs chiefly in two organs, the liver and the kidney
[101.
The importance of the kidneys in the metabolism of circulat-
ing citrate is illustrated by the fact that plasma citrate concen-
trations in experimental animals rise after nephrectomy (return-
ing to normal after 24 hours) [11]. The citrate utilized by the
kidneys is supplied predominantly by reabsorption of filtered
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citrate, with peritubular uptake of citrate accounting for the
remainder (up to 30 to 40%) of citrate utilized by the kidneys
[12]. Citrate is thought to be freely filterable at the glomerulus.
In humans, 65 to 90% of the filtered citrate is reabsorbed;
therefore 10 to 35% of filtered citrate is excreted in the urine. In
most laboratory species, the fractional excretion of citrate is
much less (such as, approximately 1% in the dog) [1, 5, 12].
Citrate reabsorption in animal studies in vivo does not appear to
be saturated until plasma levels and filtered loads of citrate are
raised several-fold [121. If all of the citrate taken up by
reabsorption of filtered citrate and by peritubular uptake of
citrate were completely metabolized, citrate could provide
approximately 10% of renal oxidative metabolism in humans
[13]; higher estimates have been made for other species. Most
of citrate taken up by the kidney does appear to be completely
metabolized to CO2 [12]. Therefore, citrate utilization repre-
sents a significant component of renal oxidative metabolism.
Extensive studies of citrate metabolism in the kidney have been
performed [reviewed in 1, 10, 14] but are beyond the scope of
this review. Most of the oxidation of citrate probably takes
place in the proximal tubule. The thick ascending limb, the only
other nephron segment examined in detail, does not appear to
metabolize citrate [15, 16], Renal cell concentrations of citrate
are higher than plasma levels of citrate, consistent with active
uptake into renal cells [1, 17]. Urinary citrate is probably
derived solely from filtered citrate which is not reabsorbed.
Citrate secretion has not been demonstrated except during
infusion of malate which may both interfere with citrate trans-
port and alter intracellular metabolism [12, 181. In most circum-
stances, urinary citrate is influenced relatively little by plasma
citrate, compared to other factors discussed below [19].
Citrate transport in the kidney
Citrate reabsorption
Early stop-flow studies suggested that the major site of citrate
reabsorption is the proximal tubule (Fig. 2) [20, 21]. However,
one stop-flow study using adult baboons suggested significant
citrate reabsorption in the distal nephron [22]. Recent studies of
ours using isolated perfused rabbit nephron segments indicated
that the proximal convoluted tubule and the proximal straight
tubule reabsorbed citrate, whereas the thick ascending limb and
cortical collecting tubule did not [18].
The mechanism of citrate reabsorption in the proximal tubule
has been characterized in exquisite detail by studies utilizing
rabbit brush border membrane vesicles [2]. The rate of citrate
transport in the brush border membrane vesicles has been
found to exceed that of sugars and amino acids studied under
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Fig. 1. Calculated divalent and trivalent citrate concentrations,
citrate2 (—) and citrate3 (———), respectively, as a function of pH and
corresponding bicarbonate concentration with a pCO2 equal 40 mm
Hg. Note that the scales for the two ionic species are nearly two orders
of magnitude different with citrate3 concentrations being much larger
than citrate2. The assumed total citrate concentration is 1 m and the
pKa3 of citrate is 5.6. Note that in a physiologic pH range citrate3
changes very little with pH. However, citrate2 concentrations change
dramatically with pH in this range.
similar conditions [23]. The apical membrane transporter re-
sponsible for citrate transport accepts a variety of Krebs cycle
intermediates; in fact, the carrier has higher affinity for the
dicarboxylate succinate [23, 24]. Most data, in fact, suggests
that citrate is transported as the divalent species, citrate2.
Citrate uptake is sodium dependent and electrogenic such that
positive charge is transported. The stoichiometry is 3 Na
transported for each citrate2 transported [reviewed in 2]. The
more predominant trivalent species citrate3 may, in fact, act
as a competitive inhibitor of divalent citrate transport [25]. The
affinity of the carrier for both citrate and the dicarboxylate
succinate is quite high (Km'S of 0.21 and 0.05 m, respectively)
[24]. However, if divalent citrate is the only transported species
as suggested, then the affinity is much high (Km is much lower)
than estimated from the total citrate concentration since the
divalent species is present at a concentration less than 10% of
the total citrate at physiologic pH. The predominant transport
of divalent citrate2 will produce a marked pH dependence of
total citrate transport (as discussed in greater detail below)
since the concentration of citrate2 is markedly pH dependent
in the physiologic pH range (Fig. 1). The specific molecular
details of the kinetics, selectivity, and binding characteristics of
the citrate or dicarboxylate carrier in the proximal tubule have
been investigated [reviewed in 2]. Citrate does not appear to
interact with a variety of other organic anion transport path-
ways in the apical membrane, including that for monocarboxy-
lates.
Many of the important aspects of citrate transport have been
confirmed by studies of intact proximal tubules. In our studies
of rabbit proximal convoluted tubules perfused in vitro, approx-
imately 80% of citrate transport was inhibited by ouabain,
consistent with a dependency on sodium transport [18]. The
component of citrate reabsorption which was not blocked by
Citrate3
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Fig. 2. Model of proximal tubule cell handling of citrate. Citrate is
reabsorbed as the divalent species across the apical membrane but may
be taken up across the peritubular membrane as the trivalent form. pH
has effects not only on citrate entry into mitochondria but also has
major effects on the concentration of the transported species. Note that
the relative magnitude of citrate reabsorption across the apical mem-
brane is greater than that of citrate uptake across the basolateral
membrane.
ouabain may represent a modest passive permeability to citrate.
The magnitude of citrate reabsorption in the perfused proximal
tubule exceeds the expected load of filtered citrate by several-
fold. However, in contrast to the brush border membrane
vesicle studies cited above, the magnitude of citrate reabsorp-
tion is much less than glucose reabsorption in the intact tubule
(both substrates studied in concentrations exceeding their re-
spective Km) [18]. In the intact tubules, citrate reabsorption
was more than 10 times higher in the proximal convoluted
tubule than in the proximal straight tubule (3.4 and 0.24
picomol/mmlmin, respectively). Also in the intact proximal
convoluted tubule, citrate reabsorption was found to be essen-
tially a unidirectional process, with no secretion of citrate [18].
Citrate reabsorption in the intact tubule is also consistent with
predominant transport of the divalent species, based on a
marked dependence on luminal pH as discussed in more detail
below [26]. Although the Km for citrate was not evaluated in the
studies of intact rabbit proximal tubules, reabsorption of citrate
at pH 7.4 was saturated at 1 mvt luminal citrate, consistent with
a Km much below 1 mM [18].
Dicarboxylate transport in the rat proximal tubule in vivo has
also been studied, using efflux of radiolabeled 2-oxoglutarate
(a-ketoglutarate) as a marker [27]. Citrate inhibited 2-oxoglut-
arate transport (K1 = 0.2 mt at pH 6.8) consistent with citrate
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transport on the same transporter as the dicarboxylate. Inhibi-
tion was predominantly via divalent citrate since inhibition was
much greater at pH 6.8 than at pH 7•7l These studies also
demonstrated that dicarboxylate transport was predominantly
sodium dependent, with a small (approximately 20%) sodium
independent reabsorption [271. The kinetics and structural
specificity of dicarboxylate transport in the rat proximal tubule
in vivo appear to be very similar to that in rabbit brush border
membrane vesicles, consistent with a single transport system
responsible for citrate reabsorption in the various species [27].
Several factors are known to alter citrate transport across the
luminal membrane of the proximal tubule (for example, acid-
base status, lithium, and starvation) and will be discussed
below.
Peritubular uptake of citrate
Numerous whole kidney studies demonstrate net peritubular
uptake of citrate, evidenced by whole kidney citrate uptake
exceeding reabsorption of filtered citrate [1, 12]. However, few
studies have explicitly addressed either citrate or dicarboxylate
transport across the basolateral membrane of renal cells. One
study did explicitly address citrate uptake in basolateral mem-
brane vesicles isolated from rabbit renal proximal tubules and
found that basolateral transport of citrate was sodium-depen-
dent but electroneutral, in contrast to the luminal transporter
[29]. The apparent affinity for citrate was also much lower (Km
of approximately 2.5 mM) than in the luminal membrane.
Interestingly, and again in contrast to the luminal membrane,
transport of citrate in basolateral vesicles was relatively insen-
sitive to pH [29]. The combination of the findings of insensitiv-
ity to pH and electroneutral transport suggests that citrate
transport across the basolateral membrane may be a coupled
transport of one citrate3 and 3 Na [29]. As seen in Figure 1,
citrate3 concentrations do not change dramatically with small
alterations in pH in the physiologic pH range.
Dicarboxylate transport in basolateral membranes from rat
kidney has also been examined (using methylsuccinate as a
substrate). Citrate inhibited methylsuccinate uptake by 60%,
indicating interaction with this dicarboxylate transport system
[30]. However, these studies [30] did not definitively indicate
that citrate is transported to a large extent on this basolateral
dicarboxylate transport system, because neither citrate trans-
port nor the detailed interaction of citrate with methylsuccinate
transport were examined. In other words, citrate may be
transported across the basolateral membrane predominantly by
a separate tricarboxylate carrier, but also have some interaction
with the basolateral dicarboxylate transporter. An in situ study
of the proximal tubule of the rat also demonstrated that citrate
inhibits basolateral dicarboxylate transport in a manner similar
to that in the luminal membrane [31]. However, again this does
not necessarily indicate that this is the predominant pathway for
peritubular uptake of citrate. A recent study (Note added in
proof) also examined succinate and citrate uptake into rabbit
basolateral membrane vesicles and confirmed several of these
findings. In these studies, citrate inhibition of succinate (or
dicarboxylate) transport was significantly less in basolateral
membranes than in brush border membranes (Note added in
proof). The basolateral transporter(s) for dicarboxylates resem-
bles the luminal transporter in lithium sensitivity and structural
specificity but differs in its pH dependence and its inducibility
by starvation [32]. Citrate inhibition of the basolateral dicar-
boxylate transporter is more pronounced at alkaline pH than at
acid pH, just the opposite from the luminal dicarboxylate
transporter [31]. The basolateral membrane is not induced by
starvation in contrast to the luminal transport mechanism.
Citrate, in contrast to some of the dicarboxylates, does not
appear to interact significantly with the basolateral PAH trans-
porter or the basolateral sulfate transporter [33]. In sum, few
studies have addressed the basolateral transport of citrate per
se and consequently the mechanisms have not been adequately
defined. Since basolateral uptake represents a significant com-
ponent of total renal uptake of citrate, this is an area of needed
work in the future.
Although filtered citrate is reabsorbed in the proximal tubule,
the basolateral uptake of citrate might allow citrate secretion in
the late proximal tubule. However, under most circumstances,
whole animal studies have not been able to provide evidence for
citrate secretion. However, during malate infusion and during
infusion of '4C-labeled precursors of citrate, evidence for
citrate secretion can be demonstrated [12, 211, and also dicar-
boxylate secretion has been measured in untreated rats [31]. In
any case, increases in urinary levels of citrate under most
physiologic circumstances probably represent a decrease in
reabsorption of filtered citrate rather than an increase in secre-
tion of citrate. For instance, in alkalosis there is no evidence for
increased peritubular transport into cells and, in fact, whole
kidney citrate utilization is decreased [12]. No citrate secretion
could be demonstrated in studies of isolated perfused proximal
convoluted tubules from rabbits [18].
Alterations in citrate transport
A variety of factors have been shown to alter urinary citrate
excretion [reviewed in 1]. Many of these factors have been
thought to act predominantly via alterations in intracellular
citrate metabolism [1]. However, many of these factors have
not been studied adequately to distinguish effects on renal
metabolism from effects on various transport pathways for
citrate. For instance, a variety of organic acids and metabolic
inhibitors increase urinary citrate and clearly increase renal
citrate concentrations due to changes in metabolism, and hence
may decrease citrate reabsorption via a decreased lumen-to-cell
citrate concentration ratio [1]. However, some of these same
organic acids and metabolic inhibitors may directly interact
with citrate transport [24]. Studies to separate components of
the metabolic and transport inhibition have not been performed.
The focus here will be on the transport effects of a limited
number of pathologic conditions or factors which have been
shown to alter citrate excretion in a significant manner.
Acid-base derangements
However, at least one study using the rat proximal tubule in vivo
has suggested that the trivalent form of citrate might be transported,
based on the fact that citrate transport did not appear to be electrogenic
[28].
Changes in acid-base balance have been known for decades
to induce marked changes in urinary citrate [1, 19, 26]. In fact,
acid-base balance appears to be the most important determinant
of urinary citrate excretion. Systemic alkalosis or alkali loading
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Fig. 3. Potential mechanisms of increased
urinary citrate with systemic alkalosis. The
contribution of these two types of effects to
the increase in urinary citrate is discussed in
the text. The opposite effects would occur
with acidosis.
cause increases in urinary citrate. Acidosis or acid loads cause
decreased urinary citrate excretion. The effect with acidosis is
not as marked in most experimental animals since the fractional
excretion of citrate is normally low even at normal pH in these
species. However in humans, the fractional excretion of citrate
is 10 to 35% and decreases in citrate excretion with acid loads
or acidosis can be marked. Patients with renal tubular acidosis
(RTA), particularly distal RTA associated with nephrocalcino-
sis, are well known to have reduced urinary excretion of citrate
[34—36]. The changes with acidosis may be particularly germane
to calcium nephrolithiasis as discussed below. Numerous ex-
perimental studies have addressed the mechanisms whereby
changes in acid-base balance alter urinary citrate excretion. The
discussion here will focus on recent studies which examine
direct effects on transport; the details of changes in renal
metabolism (which alter citrate excretion) with acid-base de-
rangements have been reviewed elsewhere [1, 10, 14].
Changes in renal metabolism have been proposed to cause
the changes in citrate excretion with acid-base imbalances [1].
Renal cortical citrate levels fall with acidosis and rise with
alkalosis [17, 19]. Also, with systemic alkalosis, increasing
intracellular pH and bicarbonate concentration inhibit renal cell
citrate oxidation by decreasing citrate entry into mitochondria
on the tricarboxylate carrier of the mitochondrial membrane [1,
37]. This results from a decreased mitochondrial pH gradient as
intracellular pH rises. The decreased mitochondrial transport
and oxidation of citrate with alkaline intracellular pH results in
increases in intracellular citrate concentration. The opposite
sequence of events occurs with acidosis. These observations
have prompted the hypothesis that the metabolic changes and
the subsequent changes in cellular citrate concentrations are the
direct cause of changes in citrate reabsorption with changes in
pH [1]. Changes in systemic pH would alter intercellular pH,
resulting in changes in intracellular citrate metabolism which
then alter citrate reabsorption and hence citrate excretion in the
urine (Fig. 3). This proposed mechanism has been widely
accepted. What is lacking in this proposal is proof that the
changes in intracellular citrate alter citrate reabsorption. In
fact, some evidence to the contrary has been provided. Fluo-
roacetate, which raises renal citrate levels, fails to alter citrate
excretion [38]. Also, a recent study of the isolated perfused
kidney disassociates renal citrate content from citrate reabsorp-
tion [39]. In these studies [39], citrate reabsorption and renal
cell content of citrate could be disassociated during changes in
plasma pH, consistent with changes in citrate reabsorption
being independent of changes in renal metabolism.2
An additional or alternative mechanism for the changes in
citrate reabsorption with acid-base derangements has been
provided by studies with proximal tubule brush border mem-
brane vesicles. Citrate uptake into brush border membrane
vesicles increases with decreasing pH [25, 29, 40, 41]. These
studies suggest that this pH sensitivity is due to changes in the
concentration of the various ionic species of citrate with pH:
citrate2, the transported species, increases with decreasing
pH. The pH sensitivity of brush border vesicle citrate transport
does not appear to result from proton gradients or from changes
in the transporter per Se. The alterations in citrate uptake in
membrane vesicles obviously do not depend on cellular metab-
olism which is eliminated in this preparation. These findings
would suggest the following scheme. Alkalosis first leads to an
increased luminal pH, both from an increased filtered bicarbon-
ate concentration, and from decreased proximal tubule proton
secretion. The increased luminal pH would decrease citrate2
concentrations which would then be the direct cause of de-
creased citrate2 reabsorption (Fig. 3). Acidosis would cause
the opposite changes. A testable feature of this scheme which
differentiates it from the metabolic effects described above is
whether luminal or cellular pH is the predominant determinant
of changes in citrate reabsorption.
Recent studies of ours directly addressed the above two
mechanisms by examining changes in citrate reabsorption with
changes in solution pH in isolated perfused rabbit proximal
convoluted tubules [26]. Solution pH was changed in either the
luminal fluid or the peritubular bathing fluid by changing the
bicarbonate concentration with constant pCO2. In these exper-
iments, decreasing peritubular pH from 7.4 to 7.2 caused an
increase in citrate reabsorption. Raising peritubular pH from
2 Also in these studies the increased renal cell citrate concentration
was shown to derive from precursors of citrate, not from uptake of
extracellular citrate [39].
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7.4 to 7.6 resulted in a fall in citrate reabsorption, consistent
with the changes observed in vivo. More importantly, the effect
of luminal pH on citrate reabsorption was examined directly in
a circumstance where peritubular pH was maintained constant.
Decreasing luminal pH from 7.4 to 7.2 increased citrate reab-
sorption and increasing perfusate pH to 7.6 decreased citrate
reabsorption. (In these in vitro tubule studies, the changes with
alkaline solutions were statistically insignificant.) Since luminal
pH has little effect on intracellular pH in the proximal tubule
[42], these data [26] demonstrate that the luminal pH in the
proximal tubule is an important direct determinant of alter-
ations in citrate reabsorption with acid-base disorders. These
effects of luminal pH are probably secondary to changes in the
concentration of the transported ionic species, citrate2. In
additional experiments, peritubular pH was decreased while
changes in luminal pH were minimized using a perfusate which
contained supraphysiologic buffering capacity. In these exper-
iments, decreasing peritubular pH did not alter citrate reabsorp-
tion, providing additional evidence of the importance of luminal
factors in the effects of acid-base disorders on citrate excretion
[26]. These results have been extended by Brennan et al in
experiments which demonstrated that changes in peritubular
pH had no additional effect on citrate reabsorption beyond that
seen with changes in luminal pH alone, again consistent with
the importance of luminal pH in determining citrate reabsorp-
tion [43]. In other experiments, amiloride in the proximal tubule
lumen decreased citrate reabsorption, probably secondary to
inhibition of luminal acidification [44]. Thus in sum, these
results demonstrate the importance of luminal pH in alterations
in citrate reabsorption with changes in acid-base balance. These
experiments do not exclude an additional component from the
metabolic changes discussed above. In fact, both mechanisms
may be valid and complementary.
An additional feature of the effect of chronic acid-base
changes on citrate reabsorption has been demonstrated in
recent studies. Jenkins and colleagues [45] demonstrated that
chronic acid loading resulted in brush border membrane vesi-
des which had enhanced citrate transport compared to control
rats. Chronic alkali loading did not alter citrate transport. Thus,
chronic adaptations in the brush border membrane transporter
may represent an additional mechanism whereby urinary citrate
is decreased in the setting of chronic acidosis.
Acetazolamide
Acetazolamide, an inhibitor of carbonic anhydrase, has been
recognized for many years to decrease urinary citrate excretion
and thereby occasionally cause calcium nephrolithiasis [46, 47].
In whole animals, acetazolamide causes an increase in urinary
citrate during the first hour followed by a decrease in urinary
citrate by the second hour [19]. Kidney levels of citrate are
decreased after three hours of acetazolamide [191. The mecha-
nism of decreased urinary citrate involves the metabolic acido-
sis resulting from acetazolamide; a decrease in urinary citrate is
prevented if acidosis is avoided [48, 49]. Also, acetazolamide
has no effect on citrate reabsorption in isolated perfused prox-
imal convoluted tubules where luminal and peritubular pH are
controlled [26].
Since acetazolamide causes urinary alkalinization despite a
systemic metabolic acidosis, some investigators have con-
cluded that urinary citrate excretion is unrelated to urine or
tubular fluid pH or bicarbonate [1, 50]. According to this view,
the systemic acidosis caused by acetazolamide would cause the
reduced urinary citrate by reducing intracellular pH. However,
despite the urinary alkalinization, a fall in proximal tubule
lumen pH may still be an important component of the mecha-
nism of the decreased urinary citrate with acetazolamide.
Luminal pH may be low during treatment with acetazolamide
due to a low plasma and glomerular filtrate concentration of
bicarbonate, and also secondary to an acid disequilibrium pH in
the lumen of the proximal tubule secondary to the inhibition of
luminal carbonic anhydrase by acetazolamide. Consequently,
acetazolamide may cause decreased urinary citrate secondary
to decreased proximal tubule luminal pH in situ.
Potassium depletion
Potassium depletion is well known to decrease urinary citrate
excretion [10, 51—53]. Potassium depletion also blocks the
increase in urinary citrate excretion which occurs with systemic
alkalosis [10, 51]. These effects of potassium depletion may be
secondary to decreased intracellular pH [54] and/or increased
H secretion during potassium depletion.
Divalent cations
Several studies in the past have shown an association be-
tween increased urinary calcium levels and increased urinary
citrate [for example, 55, 56]. Increases in urinary magnesium
may also increase urinary citrate concentrations [8]. (Also,
increasing plasma and urine citrate may increase urinary cal-
cium excretion [57, 58].) Although the relationship between
calcium and citrate is undoubtedly complex, one important
factor is undoubtedly the formation of complexes between
citrate and calcium in both plasma and urine [6, 7]. One study of
isolated brush border membrane vesicles has shown that cal-
cium influences citrate transport in a manner consistent with the
formation of complexes between calcium and citrate [25]. At
low concentrations of total citrate (physiologically relevant),
added calcium complexed with divalent citrate, reducing the
amount of citrate transport. Such effects have not been tested in
intact tubules where other more complex interactions may
occur.
Starvation
Starvation reduces urinary citrate excretion. Plasma levels
and filtered loads of citrate decreases in some species but may
increase in humans [59—61]. In vivo studies have demonstrated
that there is also increased dicarboxylate reabsorption in the
proximal tubules of starved rats [27]. Apparently the basolateral
dicarboxylate transporter (which may or may not transport
citrate as discussed above) is not enhanced in starvation [32].
Recently Windus, Cohn and Heifets have extended the studies
of starvation to demonstrate that brush border membrane
vesicles isolated from starved rats have increased citrate trans-
port consistent with an adaptive increase in the number of
citrate transporters present on the luminal membrane during
starvation [61]. This represents one of the circumstances
whereby an in vivo maneuver results in a chronic intrinsic
alteration in the apparent number of transporters present in the
apical membrane of the proximal tubule.
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Lithium
Lithium (even in therapeutic doses) has been known to
increase the urinary excretion of citrate and other Krebs cycle
intermediates in experimental animals [62]. In man, however,
therapeutic doses of lithium cause increased excretion of some
Krebs cycle intermediates such as a-ketoglutarate but in gen-
eral does not increase urinary citrate, perhaps suggesting some
species differences in citrate reabsorption in the kidney [63].
The mechanism of these effects of lithium have been demon-
strated to be secondary, at least in part, to inhibition of the
dicarboxylate transporter in the brush border membrane. Lith-
ium both competes with sodium and has non-competitive inhib-
itory effects on the transporter [64]. Lithium has also been
shown to interact with the basolateral dicarboxylate transporter
with nearly the same potency [30, 31].
Consequences of changes in urinary citrate excretion
Calcium nephrolithiasis
Calcium nephrolithiasis is the most important potential con-
sequence of a decrease in urinary citrate. A relationship be-
tween urinary citrate, urinary calcium and stone formation has
been postulated for decades [55, 65]. The details of the relation-
ship between urinary citrate and the formation of calcium
stones has recently been reviewed [4]. Briefly, citrate com-
plexes with calcium causing a reduction in ionic calcium con-
centration and hence a reduction in the saturation of calcium
oxalate and calcium phosphate. A significant percentage of
urinary calcium may be bound by citrate [46]. Citrate directly
inhibits the spontaneous nucleation of calcium oxalate and
brushite [4, 66] and also inhibits crystal growth [67]. Numerous
studies have shown that patients with calcium nephrolithiasis
have an increased incidence (19 to 63%) of low urinary citrate
[4, 5, 68, 69, 70, 71]. Many of these patients have distal renal
tubular acidosis, chronic diarrhea or malabsorption leading to
metabolic acidosis or low urinary magnesium [8. 68], thiazide
therapy with or without potassium deficiency [72, 73] or meta-
bolic acidosis from acetazolamide as discussed above. Also,
diets rich in animal protein may be associated with low urine pH
and low urinary citrate [74]. However, some patients appear to
have low urinary citrate without these associated abnormalities
[68, 75]. The mechanism of this abnormality is not known, but
decreased intestinal absorption has been suggested [9].
Conversely, administration of oral citrate, usually in the form
of potassium citrate, is used to increase urinary citrate concen-
trations [4]. Oral citrate has been shown to be effective in a
variety of types of nephrolithiasis. Potassium citrate has the
advantage over sodium citrate of also decreasing urinary cal-
cium [76]. Most of administered citrate is probably metabolized
to bicarbonate and the effect of oral citrate is the same as the
administration of another alkaline load such as bicarbonate.
Citrate and bicarbonate have been shown to have equivalent
effects on net acid excretion and plasma bicarbonate [77].
However, some of oral citrate may be absorbed and excreted in
the urine without undergoing metabolism. In considering the
use of oral citrate, clinicians should note that precautions have
recently been proposed against the indiscriminate administra-
tion of citrate-containing salts, especially in patients with renal
insufficiency; citrate apparently causes increased aluminum
absorption during simultaneous administration [78].
Acid-base balance
Not only does exogenous citrate alkalinize the urine, but
endogenous citrate excretion has some significance for acid-
base balance, at least in certain situations [79]. Total organic
anion excretion changes significantly with changes in dietary
acid and base load, and citrate represents the predominant
urinary organic anion in most species [80]. Urinary citrate
excretion represents a loss of potential base, an anion that can
be metabolized to bicarbonate. Cooke et al [81] studied the
repair of potassium depletion metabolic alkalosis in the rat with
the administration of potassium bicarbonate. The correction of
the alkalosis could be attributed in large part to citrate excretion
in the urine [81]. More recently Kaufman, Brod-Miller and
Kahn [3] studied diuretic-induced metabolic alkalosis in the rat
and found that citrate excretion in the urine increased in
proportion to increases in urinary net acid excretion and
appeared to partially prevent a further rise in plasma bicarbon-
ate. Kaufman and Kahn [82] have recently extended these
studies to show a complementary role of citrate and bicarbonate
excretion in animals with chloride and potassium depletion.
Therefore, during metabolic alkalosis in the rat, increased
urinary citrate may represent an important component of net
acid balance. In humans, citrate excretion probably does not
play the same role in acid-base balance. Although urinary
citrate excretion increases with metabolic alkalosis in humans,
the quantitative significance for acid-base balance is not equiv-
alent to that in the rat [51]. Also, the correction of metabolic
alkalosis in humans can be accounted for by changes in bicar-
bonate excretion and urinary net acid excretion, and does not
require the excretion of citrate.
Conclusion
Citrate is an interesting and important urinary organic anion
from many perspectives. Citrate is a significant substrate for
renal metabolism. In addition, the transport of citrate in the
kidney is unique: a minority ionic species is the form of citrate
that is actively transported across the proximal tubule apical
membrane. This latter phenomena also leads to an exquisite
sensitivity of transport to changes in pH. Changes in acid-base
homeostasis and other clinical derangements lead to important
changes in urinary citrate. These changes can be understood (at
least in part) on the basis of the known properties of citrate
transport and metabolism. These changes in urinary citrate are
important because urinary citrate is an important endogenous
inhibitor of calcium nephrolithiasis. Urinary citrate also con-
tributes to whole animal acid-base balance in some species.
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